JW Life Science Corp
KRX:234080
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
JW Life Science Corp
Income from Continuing Operations
JW Life Science Corp
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
JW Life Science Corp
KRX:234080
|
Income from Continuing Operations
₩28.6B
|
CAGR 3-Years
24%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Yuhan Corp
KRX:000100
|
Income from Continuing Operations
₩185.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
4%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Income from Continuing Operations
₩253.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Income from Continuing Operations
₩187.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
61%
|
CAGR 10-Years
1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Income from Continuing Operations
₩12B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-4%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Income from Continuing Operations
₩20.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
JW Life Science Corp
Glance View
JW Life Science Corp. manufactures intravenous fluids. The company is headquartered in Dangjin, Chungcheongnam-Do. The company went IPO on 2016-10-27. The firm is engaged in manufacture of basic IV fluid including water, electrolytes and glucose; nutrient infusion solution including amino acids, lipids, proteins, vitamins and minerals; and special infusion solution, which is used in special cases. The firm is also engaged in manufacture of total parenteral nutrition (TPN) products and others.
See Also
What is JW Life Science Corp's Income from Continuing Operations?
Income from Continuing Operations
28.6B
KRW
Based on the financial report for Dec 31, 2025, JW Life Science Corp's Income from Continuing Operations amounts to 28.6B KRW.
What is JW Life Science Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
8%
Over the last year, the Income from Continuing Operations growth was -35%. The average annual Income from Continuing Operations growth rates for JW Life Science Corp have been 24% over the past three years , 11% over the past five years , and 8% over the past ten years .
